EUVIMEDEUVIMED entdecken
Crossref

The FDA wants Bayesian trials, but who chooses the prior?

Lu Qian

Significance · 08.06.2026 · 23 (4) · 4-5

DOI: 10.1093/jrssig/qmag038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Significance, online erschienen am 08.06.2026. Verfasst von Lu Qian. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Earlier this year, new draft guidance from the US Food and Drug Administration encouraged the use of Bayesian methodology in clinical trials for new drugs. Lu (Maggie) Qian addresses some of the questions arising from this development

Zitieren

APA

Qian, L. (2026). The FDA wants Bayesian trials, but who chooses the prior?. Significance, 23(4), 4-5. https://doi.org/10.1093/jrssig/qmag038

Vancouver

Qian L. The FDA wants Bayesian trials, but who chooses the prior?. Significance. 2026;23(4):4-5. doi:10.1093/jrssig/qmag038

BibTeX
@article{Qian2026,
  author = {Qian, Lu},
  title = {The FDA wants Bayesian trials, but who chooses the prior?},
  journal = {Significance},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {4--5},
  doi = {10.1093/jrssig/qmag038}
}
Kostenlos starten →